Form 4: Zentalis Pharmaceuticals Executive Vincent Vultaggio Reports Stock Transactions
SEC Form 4 Filing
Vincent Vultaggio, PAO and Interim PFO of Zentalis Pharmaceuticals, reports acquisition and disposal of common stock and stock options on February 3, 2025.
Summary
- On February 3, 2025, Vincent Vultaggio, PAO and Interim PFO of Zentalis Pharmaceuticals, reported transactions involving the company's stock.
- Vultaggio acquired 158,586 shares of common stock at $0, representing restricted stock units vesting over two years.
- He also sold 2,615 shares at $1.7115 to cover tax withholding obligations related to previously granted restricted stock units.
- Additionally, Vultaggio acquired 35,633 stock options with an exercise price of $1.68, vesting monthly over four years, expiring on 02/02/2035.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions.
Industry Context
Form 4 filings are standard practice for reporting insider transactions, providing transparency to investors regarding the buying and selling activities of company executives and directors.
Stakeholder Impact
- Shareholders are informed about the insider trading activity of a key executive.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of stock transactions (acquisition and disposal of common stock and stock options). |
| 02/05/2025 | Date of signature for the Form 4 filing. |
| 02/02/2035 | Expiration date of the acquired stock options. |
Keywords
Zentalis Pharmaceuticals, ZNTL, Vincent Vultaggio, Form 4, Stock Transactions, Restricted Stock Units, Stock Options, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.